Sinofn Health
Sinofn Health
Milan stands at the epicentre of Europe's healthcare innovation. As the capital of Lombardy, one of the wealthiest regions in Italy, it boasts a sophisticated medical infrastructure that increasingly demands Foods for Special Medical Purposes (FSMP). The clinical nutrition market in Italy is undergoing a shift towards personalized care, particularly in metabolic disorders and geriatric nutrition.
From the metabolic clinics of Ospedale Maggiore Policlinico to home-care solutions for the aging population in Northern Italy, the demand for high-quality, bio-available nutrition is surging. Our FSMP manufacturing solutions are designed to cater to this specific regulatory environment (aligned with EFSA guidelines), ensuring that dietary management for PKU, dysphagia, and chronic metabolic diseases is both compliant and clinically effective.
Many brands in Milan are looking for production partners who offer more than just low-cost manufacturing. They require resilience—the ability to maintain consistent supply chains despite global disruptions. SINOFN leverages advanced Chinese manufacturing capabilities, backed by the Chinese Academy of Sciences (CAS), to provide industrial-scale production that European brands can rely on.
Our R&D roadmap focuses on the integration of artificial intelligence in formulation. We are exploring the intersection of nutraceuticals and personalized health, developing formulations that can be tailored to the Italian demographic's specific dietary profiles. By leveraging high-throughput screening and stability testing, we reduce the time-to-market for innovative Italian brands.
One of our key differentiators in the Milan market is our commitment to cross-continental expertise. Our lead formulation expert, Hans van Dijk (Netherlands), bridges the gap between EU regulatory compliance and Asian manufacturing efficiency. This ensures that every product leaving our factory is "European-ready" from day one.
Led by Dr. Zhang Ying (CAS) and Dr. Tan Shengjie (Peking University Medical School), our R&D team provides the clinical evidence necessary to support FSMP claims, a crucial requirement for market entry in Italy and the wider EU.
1. How does your FSMP production align with EU regulations for the Milan market?
Our processes adhere to strict HACCP, ISO 22000, and FSSC 22000 standards. With our EU regulatory specialist (Hans van Dijk), we ensure all formulation data and safety documentation meet the requirements of the European Food Safety Authority (EFSA).
2. Can you scale production for Milan-based startups vs. established brands?
Absolutely. We support both pilot-scale prototyping for new market entries and high-volume industrial manufacturing for established nutraceutical brands, ensuring flexibility in batch sizes.
3. What makes your China-based factory different from others?
Our foundation in the Chinese Academy of Sciences provides a competitive advantage in R&D and intellectual property. We combine top-tier scientific innovation with a highly resilient supply chain that guarantees consistent, high-quality production for global clients.
